# Filing Detail

Form PRE 14A - Other preliminary proxy statements:
SEC Accession No. 0000950170-24-044806
Filing Date
2024-04-16
Accepted
2024-04-16 16:30:23
Documents
17
Period of Report
2024-06-07

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | PRE 14A | akro-20240416.htm iXBRL | PRE 14A | 1541723
2 | GRAPHIC | img235425615_0.jpg | GRAPHIC | 13695
3 | GRAPHIC | img235425615_1.jpg | GRAPHIC | 70754
4 | GRAPHIC | img235425615_2.jpg | GRAPHIC | 70894
5 | GRAPHIC | img235425615_3.jpg | GRAPHIC | 274295
6 | GRAPHIC | img235425615_4.jpg | GRAPHIC | 177621
| Complete submission text file | 0000950170-24-044806.txt |  | 3497536

Data Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
7 | XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT | akro-20240416.xsd | EX-101.SCH | 27091
20 | EXTRACTED XBRL INSTANCE DOCUMENT | akro-20240416_htm.xml | XML | 78278

Mailing Address 601 GATEWAY BOULEVARD, SUITE 350 SOUTH SAN FRANCISCO CA 94080
Business Address 601 GATEWAY BOULEVARD, SUITE 350 SOUTH SAN FRANCISCO CA 94080 650-487-6488
Akero Therapeutics, Inc. (Filer) CIK: 0001744659 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: PRE 14A | Act: 34 | File No.: 001-38944 | Film No.: 24848173
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)